MeSH term
Frequency | Condition_Probility | Adolescent | 94 | 0.0 |
Humans | 748 | 0.0 |
Male | 324 | 0.0 |
Tomography, X-Ray Computed | 6 | 0.0 |
Aged | 162 | 0.0 |
Aged, 80 and over | 46 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Female | 340 | 0.0 |
United States | 5 | 0.0 |
Cells, Cultured | 61 | 0.0 |
Child, Preschool | 43 | 0.0 |
Comparative Study | 101 | 0.0 |
Fibroblasts/metabolism/ultrastructure | 2 | 11.0 |
Infant | 33 | 0.0 |
Membrane Proteins/*genetics | 3 | 0.0 |
Mutation/*genetics | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 357 | 0.0 |
Adult | 261 | 0.0 |
Child | 65 | 0.0 |
Forced Expiratory Volume | 2 | 2.0 |
Homozygote | 2 | 0.0 |
Middle Aged | 240 | 0.0 |
Neutrophils/*enzymology | 3 | 2.0 |
Vital Capacity | 2 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Combined Modality Therapy | 16 | 1.0 |
Salvage Therapy | 2 | 2.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Cell Line | 27 | 0.0 |
*DNA Methylation | 2 | 0.0 |
DNA Primers | 12 | 0.0 |
DNA, Satellite/*genetics | 2 | 3.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Protein Conformation | 20 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Transfection | 10 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Questionnaires | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 136 | 0.0 |
Animals | 165 | 0.0 |
Electron Transport Complex II | 8 | 30.0 |
Mitochondria/drug effects/metabolism | 2 | 6.0 |
Multienzyme Complexes/metabolism | 7 | 3.0 |
Oxidative Phosphorylation | 9 | 26.0 |
Oxidoreductases/metabolism | 5 | 7.0 |
Succinate Dehydrogenase/metabolism | 6 | 17.0 |
Immunohistochemistry | 64 | 0.0 |
Regression Analysis | 4 | 0.0 |
Time Factors | 33 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Collagen Type IV/metabolism | 4 | 19.0 |
Gelatinase A/metabolism | 2 | 3.0 |
Statistics, Nonparametric | 4 | 0.0 |
Age Factors | 17 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 4 | 0.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Cisplatin/administration & dosage | 4 | 1.0 |
Infant, Newborn | 26 | 0.0 |
Injections, Intravenous | 3 | 0.0 |
Neoplasm Staging | 35 | 1.0 |
Survival Rate | 17 | 0.0 |
Treatment Outcome | 20 | 0.0 |
Antibodies/*analysis | 3 | 2.0 |
Basement Membrane/immunology | 5 | 9.0 |
Enzyme-Linked Immunosorbent Assay | 21 | 0.0 |
Base Sequence | 49 | 0.0 |
DNA, Mitochondrial/metabolism | 2 | 16.0 |
*Electron Transport | 3 | 33.0 |
Mitochondria/*metabolism | 12 | 7.0 |
Mutation | 19 | 0.0 |
Brain/pathology | 4 | 1.0 |
DNA, Mitochondrial/*metabolism | 3 | 23.0 |
Electron Transport Complex I | 7 | 18.0 |
Electron Transport Complex III/metabolism | 6 | 42.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Mitochondria, Muscle/enzymology | 2 | 18.0 |
Muscle, Skeletal/metabolism | 3 | 1.0 |
NADH, NADPH Oxidoreductases/metabolism | 5 | 17.0 |
Energy Metabolism | 3 | 1.0 |
Prospective Studies | 15 | 0.0 |
DNA, Mitochondrial/*genetics | 12 | 11.0 |
English Abstract | 107 | 0.0 |
Mitochondria, Muscle/*metabolism | 3 | 25.0 |
Sequence Deletion | 6 | 0.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
Lymphatic Metastasis | 5 | 0.0 |
Neoplasm Invasiveness | 8 | 0.0 |
Chromatography, High Pressure Liquid | 7 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Hydrogen-Ion Concentration | 15 | 1.0 |
Kinetics | 33 | 0.0 |
Models, Chemical | 3 | 0.0 |
Pressure | 2 | 1.0 |
Rabbits | 19 | 0.0 |
Temperature | 6 | 0.0 |
Ultraviolet Rays | 2 | 0.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Molecular Structure | 3 | 0.0 |
Rats | 32 | 0.0 |
Rats, Wistar | 8 | 0.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 2 | 6.0 |
*Gene Expression | 5 | 0.0 |
Paclitaxel/*therapeutic use | 2 | 13.0 |
Body Mass Index | 3 | 0.0 |
Cholesterol/blood | 17 | 1.0 |
Lipids/*blood | 6 | 1.0 |
Lipoproteins, HDL Cholesterol/blood | 5 | 0.0 |
Phenotype | 14 | 0.0 |
Triglycerides/blood | 16 | 1.0 |
Autopsy | 5 | 2.0 |
Biopsy | 17 | 1.0 |
Fibrosis | 7 | 4.0 |
Retrospective Studies | 28 | 0.0 |
Transplantation, Homologous | 2 | 0.0 |
Certification | 2 | 50.0 |
Incidence | 4 | 0.0 |
Japan/epidemiology | 4 | 1.0 |
Societies, Medical | 2 | 7.0 |
Case-Control Studies | 3 | 0.0 |
Follow-Up Studies | 17 | 0.0 |
Sensitivity and Specificity | 10 | 0.0 |
Amino Acid Sequence | 57 | 0.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 16 | 0.0 |
Bacterial Adhesion | 2 | 3.0 |
Bacterial Proteins/metabolism | 2 | 3.0 |
Collagen Type I/metabolism | 3 | 8.0 |
Collagen Type V/metabolism | 2 | 100.0 |
Integrins/*metabolism | 4 | 2.0 |
Protein Binding | 16 | 0.0 |
Receptors, Collagen | 2 | 2.0 |
Species Specificity | 9 | 0.0 |
Prognosis | 37 | 0.0 |
Statistics | 5 | 1.0 |
Liver Transplantation/*methods | 2 | 28.0 |
Liver/enzymology | 3 | 0.0 |
Solubility | 6 | 0.0 |
Swine | 5 | 0.0 |
Carbohydrate Sequence | 4 | 1.0 |
Cloning, Molecular | 14 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Gene Expression | 11 | 0.0 |
In Vitro | 18 | 0.0 |
Mice | 43 | 0.0 |
Molecular Sequence Data | 69 | 0.0 |
Oligosaccharides/chemistry/metabolism | 2 | 13.0 |
Pregnancy | 29 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Sequence Homology, Amino Acid | 18 | 0.0 |
Spodoptera | 3 | 1.0 |
Substrate Specificity | 14 | 0.0 |
Tissue Distribution | 16 | 0.0 |
Antibody Specificity | 13 | 0.0 |
Collagen/immunology | 3 | 11.0 |
Kidney Glomerulus/*immunology | 3 | 12.0 |
Catalysis | 8 | 1.0 |
DNA, Mitochondrial/genetics | 9 | 18.0 |
*Oxidative Phosphorylation | 5 | 50.0 |
Amino Acid Motifs | 3 | 0.0 |
*Brain Chemistry | 3 | 1.0 |
Circular Dichroism | 4 | 0.0 |
Models, Molecular | 11 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Cardiac Pacing, Artificial | 2 | 4.0 |
*Carrier Proteins | 2 | 0.0 |
Citrate (si)-Synthase/metabolism | 4 | 6.0 |
Dogs | 6 | 0.0 |
Electron Transport Complex III/analysis | 3 | 100.0 |
Gene Deletion | 4 | 0.0 |
Mitochondria, Muscle/metabolism | 2 | 20.0 |
Multienzyme Complexes/*analysis | 2 | 33.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Succinate Dehydrogenase/analysis | 2 | 33.0 |
Gene Frequency | 3 | 0.0 |
Genotype | 7 | 0.0 |
Pedigree | 10 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Membrane Glycoproteins/analysis | 5 | 1.0 |
Oligosaccharides/metabolism | 2 | 4.0 |
Polysaccharides/*biosynthesis | 2 | 22.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Genetic Complementation Test | 3 | 0.0 |
Mammals | 2 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Creatinine/blood | 2 | 0.0 |
Glucose/pharmacology | 2 | 1.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Reference Values | 19 | 0.0 |
Superoxide Dismutase/genetics/*metabolism | 2 | 4.0 |
Blotting, Western | 23 | 0.0 |
CHO Cells | 4 | 0.0 |
Epitopes/*chemistry | 2 | 11.0 |
Flow Cytometry | 6 | 0.0 |
Hamsters | 7 | 0.0 |
Ligands | 8 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Solvents | 2 | 3.0 |
Drug Administration Schedule | 10 | 1.0 |
*Tomography, X-Ray Computed | 2 | 2.0 |
Liver/chemistry/pathology | 2 | 12.0 |
Extracellular Matrix/metabolism | 4 | 2.0 |
Recurrence | 5 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Calcium/*metabolism | 4 | 0.0 |
*Bacterial Proteins | 2 | 1.0 |
*Escherichia coli Proteins | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Binding Sites | 17 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Platelet Aggregation/*drug effects | 2 | 1.0 |
Polymerase Chain Reaction | 16 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Enzyme Activation | 5 | 0.0 |
Fibroblasts | 4 | 0.0 |
Hydrolysis | 7 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Sulfhydryl Reagents/pharmacology | 2 | 4.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Precipitin Tests | 6 | 0.0 |
Mortality | 2 | 6.0 |
Stroke Volume/drug effects | 2 | 6.0 |
Quality of Life | 2 | 1.0 |
Diagnostic Errors | 2 | 2.0 |
HL-60 Cells | 2 | 0.0 |
Comorbidity | 2 | 0.0 |
Peptide Fragments/immunology | 3 | 1.0 |
Enzyme Activation/physiology | 2 | 1.0 |
Binding, Competitive | 6 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Glycosylation | 4 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Registries | 2 | 0.0 |
Survival Analysis | 20 | 0.0 |
Antibody Formation | 2 | 0.0 |
Cancer Vaccines/*immunology | 2 | 3.0 |
Disease-Free Survival | 5 | 0.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Risk Factors | 8 | 0.0 |
Phosphorylation | 5 | 0.0 |
Analysis of Variance | 14 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
Collagen/*physiology | 4 | 20.0 |
Electrophoresis, Polyacrylamide Gel | 27 | 0.0 |
RNA, Messenger | 4 | 0.0 |
Collagen/metabolism | 11 | 4.0 |
Enzyme Stability | 2 | 1.0 |
Oligopeptides/metabolism | 2 | 3.0 |
Electrocardiography | 6 | 1.0 |
Prevalence | 3 | 0.0 |
Risk Assessment | 3 | 0.0 |
Protein Folding | 2 | 0.0 |
Cattle | 16 | 0.0 |
Lung/chemistry | 2 | 7.0 |
Structure-Activity Relationship | 9 | 0.0 |
HLA-DR Antigens/*genetics | 3 | 0.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 3 | 1.0 |
Immunoenzyme Techniques | 19 | 0.0 |
Rats, Long-Evans | 2 | 4.0 |
Aging | 3 | 0.0 |
Glial Fibrillary Acidic Protein/*metabolism | 2 | 6.0 |
Carcinoma, Non-Small-Cell Lung/mortality/*pathology/surgery | 3 | 60.0 |
Lung Neoplasms/mortality/*pathology/surgery | 2 | 50.0 |
Neoplasm Staging/*methods | 4 | 11.0 |
*Pneumonectomy | 2 | 33.0 |
Protein Denaturation | 2 | 0.0 |
Adenosinetriphosphatase/metabolism | 2 | 1.0 |
Mitochondria, Heart/enzymology | 2 | 28.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Actins/analysis | 2 | 1.0 |
Antigens, CD/analysis | 3 | 0.0 |
Collagen/analysis | 12 | 16.0 |
Fibronectins/analysis | 7 | 13.0 |
Tenascin/analysis | 2 | 33.0 |
Longitudinal Studies | 2 | 0.0 |
Vaginal Smears | 5 | 7.0 |
Double-Blind Method | 5 | 0.0 |
Electrocardiography, Ambulatory | 2 | 6.0 |
Heart Rate/drug effects | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Basement Membrane/metabolism | 11 | 17.0 |
Collagen/genetics/*metabolism | 2 | 18.0 |
In Situ Hybridization | 7 | 0.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Ethanol/pharmacology | 2 | 3.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Neoplasm Metastasis | 6 | 0.0 |
Electron Transport | 17 | 27.0 |
Lymphocytes/*enzymology | 3 | 4.0 |
Mitochondria/*enzymology | 4 | 3.0 |
Collagen/genetics | 4 | 4.0 |
Alleles | 8 | 0.0 |
Dose-Response Relationship, Drug | 13 | 0.0 |
Polymorphism, Genetic | 5 | 0.0 |
Protein Isoforms | 4 | 0.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Adenocarcinoma/*metabolism/pathology | 3 | 2.0 |
Basement Membrane/*metabolism | 5 | 35.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Collagen/classification/*metabolism | 3 | 75.0 |
Disease Progression | 5 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Chromosome Mapping | 11 | 0.0 |
Conserved Sequence | 5 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Phylogeny | 5 | 0.0 |
Antineoplastic Agents/*administration & dosage/adverse effects | 3 | 18.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology | 2 | 10.0 |
Infusions, Intravenous | 3 | 0.0 |
Lung Neoplasms/*drug therapy/pathology | 3 | 9.0 |
Collagen/genetics/metabolism | 2 | 13.0 |
Fibronectins/genetics/metabolism | 2 | 25.0 |
*Gene Expression Regulation | 7 | 0.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Signal Transduction | 4 | 0.0 |
Exons | 9 | 0.0 |
*Genes, p53 | 3 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
*Mutation | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Smoking | 6 | 1.0 |
*Gastrectomy | 2 | 8.0 |
Stomach Neoplasms/*mortality/pathology/surgery | 2 | 66.0 |
Binding Sites/genetics | 2 | 0.0 |
Electron Transport Complex IV/metabolism | 5 | 11.0 |
Buffers | 2 | 1.0 |
Solutions | 2 | 1.0 |
Lymphocyte Activation | 3 | 0.0 |
Obesity/*complications | 2 | 11.0 |
*Prenatal Exposure Delayed Effects | 2 | 4.0 |
Cell Division | 7 | 0.0 |
Microscopy, Electron | 30 | 1.0 |
Microscopy, Electron, Scanning | 3 | 1.0 |
Arm | 3 | 9.0 |
Cyclophosphamide/administration & dosage | 3 | 1.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Methotrexate/administration & dosage | 3 | 3.0 |
Radiotherapy/adverse effects | 3 | 8.0 |
Collagen/*analysis | 18 | 50.0 |
Fetus | 4 | 0.0 |
Collagen/*metabolism | 22 | 14.0 |
Postoperative Complications/etiology | 2 | 5.0 |
Myocardium/metabolism | 4 | 1.0 |
Brain/*metabolism | 3 | 0.0 |
Lipid Peroxidation | 2 | 1.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Antibodies, Monoclonal | 15 | 0.0 |
*Collagen Type IV | 4 | 33.0 |
Fluorescent Antibody Technique | 37 | 1.0 |
Gelatinase B | 4 | 5.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Hela Cells | 8 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Escherichia coli/genetics | 2 | 0.0 |
Molecular Weight | 17 | 0.0 |
Subcellular Fractions/enzymology | 2 | 2.0 |
Apoptosis | 2 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
Enzyme Induction | 3 | 0.0 |
Mitochondria/enzymology/*metabolism | 2 | 25.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Blotting, Northern | 10 | 0.0 |
Blotting, Southern | 5 | 0.0 |
Isoenzymes/*genetics | 3 | 0.0 |
Kidney/enzymology | 2 | 1.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Fibroblasts/*metabolism | 3 | 1.0 |
Hydrolases/metabolism | 2 | 14.0 |
Lysosomes/enzymology | 2 | 3.0 |
Breast Neoplasms/*metabolism | 3 | 1.0 |
Isomerism | 2 | 0.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Staining and Labeling | 5 | 0.0 |
Collagen/*biosynthesis | 2 | 5.0 |
Fibronectins/metabolism | 10 | 5.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Reproducibility of Results | 8 | 0.0 |
Proton-Translocating ATPases/metabolism | 2 | 18.0 |
Mitochondria, Muscle/*enzymology | 5 | 45.0 |
Coculture Techniques | 2 | 0.0 |
Collagen/biosynthesis/*genetics | 2 | 6.0 |
Fibroblasts/cytology/physiology | 2 | 2.0 |
*Heparan Sulfate Proteoglycan | 2 | 7.0 |
Models, Biological | 2 | 0.0 |
Skin Physiology | 2 | 5.0 |
DNA, Viral/*analysis | 2 | 2.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Cell Survival/drug effects | 2 | 0.0 |
Lipid Peroxidation/drug effects | 2 | 3.0 |
Oligopeptides/pharmacology | 3 | 1.0 |
Oxygen Consumption | 4 | 1.0 |
Administration, Oral | 3 | 0.0 |
*Bacterial Adhesion | 2 | 4.0 |
Collagen | 3 | 1.0 |
Drug Combinations | 3 | 0.0 |
Epithelial Cells | 4 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Hepacivirus/*genetics | 3 | 12.0 |
Ambulatory Care | 2 | 6.0 |
Drug Therapy, Combination | 6 | 0.0 |
Calcitriol/pharmacology | 2 | 1.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Forskolin/pharmacology | 4 | 1.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Fibroblasts/metabolism | 10 | 1.0 |
Antigens, Human Platelet/*analysis | 2 | 40.0 |
Genetic Vectors | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Hypertension/complications | 2 | 3.0 |
Placebos | 2 | 0.0 |
*Renal Dialysis | 3 | 0.0 |
Liver/*enzymology | 3 | 0.0 |
Oxidation-Reduction | 6 | 0.0 |
Age Distribution | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Kidney Glomerulus/*metabolism/pathology | 2 | 15.0 |
Protein Biosynthesis | 2 | 0.0 |
Calcium/metabolism/*physiology | 2 | 8.0 |
Evolution, Molecular | 2 | 0.0 |
Hybrid Cells/metabolism | 2 | 5.0 |
Rotenone/pharmacology | 2 | 22.0 |
Basement Membrane/pathology | 2 | 5.0 |
Collagen/genetics/*immunology | 2 | 50.0 |
*Linkage (Genetics) | 4 | 0.0 |
*X Chromosome | 4 | 0.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Nucleic Acid Conformation | 3 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
Chronic Disease | 6 | 0.0 |
Europe | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Electron Transport Complex IV/genetics | 2 | 18.0 |
Genes, Structural | 7 | 0.0 |
Syndrome | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 11 | 0.0 |
Antibodies, Monoclonal/immunology | 7 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Chlamydia trachomatis | 3 | 50.0 |
Immunophenotyping | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 3 | 0.0 |
*Chromosomes | 2 | 3.0 |
*Chromosomes, Human, Pair 13 | 3 | 1.0 |
Gestational Age | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Biological Availability | 2 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Histocytochemistry | 12 | 1.0 |
Heart/embryology | 2 | 3.0 |
Linkage (Genetics) | 3 | 0.0 |
Antigens, CD26/*metabolism | 2 | 9.0 |
Epithelial Cells/enzymology | 2 | 5.0 |
Macrophages, Alveolar/*enzymology | 2 | 22.0 |
Protease Inhibitors/pharmacology | 3 | 1.0 |
Gene Expression Regulation | 5 | 0.0 |
Antibodies/immunology | 2 | 0.0 |
Epitopes/immunology | 6 | 1.0 |
Fibronectins/*metabolism | 5 | 7.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Laminin/*metabolism | 9 | 26.0 |
Radioimmunoassay | 6 | 0.0 |
Lymph Node Excision | 3 | 4.0 |
Chromosomes, Human, Pair 7 | 3 | 1.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
Rats, Inbred Lew | 2 | 0.0 |
Collagen/immunology/*metabolism | 4 | 66.0 |
Immunoblotting | 5 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Calcium/metabolism | 5 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Collagen/chemistry/*metabolism | 2 | 33.0 |
Actuarial Analysis | 2 | 2.0 |
Transplantation, Autologous | 2 | 0.0 |
Cytochrome-c Oxidase Deficiency | 4 | 40.0 |
*Evolution, Molecular | 2 | 0.0 |
*Multigene Family | 4 | 0.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Fibronectins/genetics | 5 | 16.0 |
Vimentin/analysis | 3 | 1.0 |
Placenta/metabolism | 2 | 1.0 |
Phosphodiesterase Inhibitors/*pharmacology | 3 | 6.0 |
DNA Restriction Enzymes | 6 | 1.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
Oligomycins/pharmacology | 2 | 25.0 |
Basement Membrane/*chemistry | 4 | 100.0 |
Integrins/*analysis | 2 | 8.0 |
Laminin/*analysis | 6 | 54.0 |
Antihypertensive Agents/pharmacology | 2 | 4.0 |
Drug Synergism | 2 | 0.0 |
*Peptides | 2 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 2 | 4.0 |
Lipids/*metabolism | 2 | 0.0 |
Mitochondria, Liver/*enzymology | 2 | 7.0 |
NAD(P)H Dehydrogenase (Quinone)/metabolism | 3 | 10.0 |
Radiation Dosage | 3 | 3.0 |
Extracellular Matrix/*metabolism | 6 | 6.0 |
von Willebrand Factor/*metabolism | 2 | 0.0 |
Polymers | 2 | 1.0 |
Precipitation | 2 | 1.0 |
Cell Membrane/enzymology | 3 | 1.0 |
Microscopy, Immunoelectron | 6 | 1.0 |
Singapore/epidemiology | 2 | 6.0 |
Autoantibodies/*blood | 2 | 0.0 |
Annexin A2/*metabolism | 2 | 66.0 |
Annexin A5/metabolism | 2 | 2.0 |
Macromolecular Substances | 13 | 0.0 |
DNA Probes | 6 | 0.0 |
Glomerular Mesangium/cytology/drug effects/*metabolism | 2 | 40.0 |
Chromatography, Affinity | 4 | 0.0 |
Cross Reactions | 8 | 0.0 |
Liver Cirrhosis, Alcoholic/metabolism | 2 | 28.0 |
Platelet Count | 3 | 0.0 |
Extracellular Matrix/metabolism/*physiology | 2 | 50.0 |
Pregnancy Trimester, First | 2 | 0.0 |
Chagas Cardiomyopathy/*immunology | 2 | 40.0 |
Chagas Disease/*immunology | 2 | 11.0 |
Blood Pressure/drug effects | 2 | 0.0 |
*Laryngoscopy | 2 | 66.0 |
Extracellular Matrix/*chemistry | 7 | 38.0 |
Procollagen/analysis | 4 | 40.0 |
Sex Factors | 7 | 0.0 |
Annexin A5/*metabolism | 3 | 33.0 |
Calcimycin/pharmacology | 2 | 0.0 |
Calcium/physiology | 2 | 0.0 |
Cell Compartmentation | 3 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Epitopes/analysis/immunology | 2 | 10.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Italy | 2 | 0.0 |
Skin/metabolism | 2 | 1.0 |
Clinical Trials | 7 | 0.0 |
Hyperlipidemia/*drug therapy | 2 | 6.0 |
Fibronectins/*analysis | 8 | 36.0 |
Autoantigens/immunology | 2 | 1.0 |
Goodpasture Syndrome/*immunology | 3 | 42.0 |
Neurokinin A/*metabolism | 2 | 100.0 |
Substance P/*metabolism | 2 | 6.0 |
Annexins/*metabolism | 4 | 66.0 |
Antilipemic Agents/*therapeutic use | 2 | 2.0 |
Lipids/blood | 10 | 1.0 |
Lipoproteins/blood/drug effects | 2 | 14.0 |
Lipoprotein(a)/*blood | 2 | 2.0 |
Basement Membrane/chemistry | 6 | 30.0 |
Cell Adhesion | 7 | 0.0 |
*Genes, Structural | 6 | 0.0 |
Mice/*genetics | 3 | 1.0 |
Feasibility Studies | 3 | 1.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Collagen/*genetics | 11 | 2.0 |
X Chromosome | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel/methods | 3 | 2.0 |
Disulfides/chemistry | 2 | 2.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Extracellular Matrix Proteins/*metabolism | 3 | 4.0 |
Proteoglycans/*metabolism | 2 | 3.0 |
*Composite Resins | 2 | 40.0 |
Dental Restoration, Permanent/*methods | 2 | 25.0 |
Alternative Splicing | 2 | 0.0 |
Hominidae/*genetics | 2 | 1.0 |
Introns | 3 | 0.0 |
Collagen/*analysis/immunology | 3 | 60.0 |
Blood Glucose/analysis | 3 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 3 | 0.0 |
Diagnosis, Differential | 6 | 0.0 |
Neoplasm Proteins/analysis | 3 | 0.0 |
Surface Properties | 2 | 1.0 |
Densitometry | 5 | 3.0 |
Cyanogen Bromide | 4 | 6.0 |
Immunoassay | 2 | 0.0 |
Cell Differentiation | 4 | 0.0 |
Collagen/*blood | 2 | 9.0 |
Random Allocation | 3 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
*Protein Conformation | 3 | 1.0 |
Variation (Genetics) | 4 | 0.0 |
Magnesium/pharmacology | 2 | 1.0 |
Kidney Glomerulus/*metabolism | 3 | 9.0 |
Karyotyping | 2 | 0.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
*Trisomy | 2 | 1.0 |
Alanine Transaminase/blood | 3 | 1.0 |
Biopsy, Needle | 2 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Extracellular Matrix Proteins/*analysis | 5 | 26.0 |
Tenascin | 2 | 18.0 |
Acetates | 2 | 28.0 |
Plant Extracts/*pharmacology | 2 | 2.0 |
Electron Transport Complex III/*analysis | 2 | 100.0 |
NAD(P)H Dehydrogenase (Quinone)/*analysis | 2 | 66.0 |
Blood Preservation/*methods | 2 | 8.0 |
Thrombospondins | 3 | 2.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Restriction Mapping | 9 | 0.0 |
Serotyping | 3 | 1.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Blood Platelets/*metabolism | 3 | 1.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Half-Life | 3 | 0.0 |
Collagen/*analysis/biosynthesis | 2 | 100.0 |
Intermediate Filament Proteins/*analysis | 2 | 10.0 |
Mice, Nude | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
Aging/*metabolism | 3 | 1.0 |
Organ Specificity | 5 | 0.0 |
Blood Pressure/physiology | 2 | 1.0 |
Kidney Glomerulus/*pathology | 2 | 10.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Peptide Fragments/chemical synthesis/*pharmacology | 2 | 13.0 |
Chromatography, DEAE-Cellulose | 2 | 3.0 |
Electron Transport Complex IV/*biosynthesis/genetics | 2 | 100.0 |
Muscles/pathology | 3 | 7.0 |
Antibody Specificity/immunology | 2 | 3.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Collagen/*immunology | 6 | 31.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Parkinson Disease/*metabolism | 2 | 7.0 |
Laminin/analysis | 6 | 19.0 |
Radiotherapy Dosage | 4 | 2.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Cardiotonic Agents/*pharmacology | 2 | 12.0 |
Pyridones/*pharmacology | 2 | 28.0 |
Antigens, CD36 | 2 | 1.0 |
Blood Platelets/immunology | 2 | 2.0 |
*Platelet Adhesiveness | 2 | 4.0 |
Postoperative Complications | 4 | 2.0 |
Extracellular Matrix/*physiology | 2 | 4.0 |
Cytosol/enzymology | 3 | 1.0 |
Muscle Relaxation/drug effects | 2 | 8.0 |
Nitroprusside/pharmacology | 2 | 2.0 |
Purinones/pharmacology | 2 | 18.0 |
Pyridazines/pharmacology | 2 | 25.0 |
Pyrrolidinones/pharmacology | 2 | 3.0 |
Rolipram | 2 | 7.0 |
Hydrolases/*metabolism | 2 | 33.0 |
Heparan Sulfate Proteoglycan | 2 | 6.0 |
Nephritis, Hereditary/*genetics | 2 | 5.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Proteins/analysis | 2 | 1.0 |
Parkinson Disease/*enzymology | 2 | 18.0 |
Fibrinogen/metabolism | 2 | 0.0 |
Chromosome Deletion | 4 | 0.0 |
Muscle, Skeletal/enzymology/*pathology | 2 | 40.0 |
Hepatectomy/*methods | 4 | 33.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Hydrogen Bonding | 2 | 1.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Protons | 2 | 2.0 |
Glycosaminoglycans/biosynthesis | 2 | 28.0 |
Fatty Acids, Omega-3/*administration & dosage | 2 | 15.0 |
Action Potentials/physiology | 2 | 4.0 |
Neural Conduction/physiology | 2 | 5.0 |
Reaction Time | 2 | 1.0 |
DNA | 5 | 0.0 |
Amyotrophic Lateral Sclerosis/enzymology/genetics/*metabolism | 2 | 66.0 |
Family | 2 | 0.0 |
Mexico/epidemiology | 2 | 6.0 |
Connective Tissue/chemistry | 2 | 28.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Hypercholesterolemia/blood | 2 | 10.0 |
Antigens, Differentiation/analysis | 2 | 0.0 |
*Collagen | 4 | 11.0 |
Thermodynamics | 2 | 0.0 |
Immunoglobulin G/*immunology | 2 | 2.0 |
Heart Rate/physiology | 2 | 2.0 |
Isoenzymes/antagonists & inhibitors/*metabolism | 2 | 5.0 |
Chickens | 4 | 0.0 |
Collagen/*chemistry/genetics | 2 | 40.0 |
Homeostasis | 2 | 0.0 |
Insulin/blood | 2 | 0.0 |
Mass Screening | 3 | 1.0 |
DNA/*genetics | 4 | 1.0 |
Gene Library | 5 | 0.0 |
Oxidoreductases/*analysis | 3 | 37.0 |
Collagen/*genetics/metabolism | 2 | 5.0 |
Serologic Tests | 2 | 2.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Antibodies | 3 | 0.0 |
Peptides/pharmacology | 2 | 1.0 |
Laminin/*genetics | 2 | 4.0 |
Fibroblasts/enzymology | 5 | 2.0 |
Mitochondria/enzymology | 2 | 1.0 |
Enkephalins/metabolism | 2 | 22.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
*Antigenic Variation | 2 | 20.0 |
Epitopes | 5 | 0.0 |
Hemagglutination Inhibition Tests | 3 | 6.0 |
Antigens, Protozoan/*immunology | 2 | 5.0 |
Plasmodium falciparum/*immunology | 2 | 4.0 |
Hyperlipidemia/blood/*drug therapy | 3 | 13.0 |
Nucleic Acid Hybridization | 11 | 0.0 |
Cardiomyopathy, Dilated/*physiopathology | 2 | 28.0 |
Arteriosclerosis/*metabolism/pathology | 4 | 10.0 |
Rats, Inbred Strains | 2 | 0.0 |
Myocardium/*chemistry | 3 | 12.0 |
Apolipoproteins B/*genetics | 2 | 1.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Proteoglycans/metabolism | 2 | 2.0 |
Rats/*metabolism | 2 | 25.0 |
Escherichia coli/enzymology | 2 | 3.0 |
Hyperlipoproteinemia/blood/*drug therapy | 2 | 40.0 |
Lipoproteins/blood | 6 | 1.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Reoperation | 3 | 2.0 |
NADH Dehydrogenase/metabolism | 2 | 20.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Kidney Diseases/*metabolism/pathology | 2 | 16.0 |
Electron Transport Complex IV/analysis | 2 | 16.0 |
Brain Mapping | 2 | 1.0 |
Cats | 4 | 1.0 |
Electroencephalography | 2 | 0.0 |
Evoked Potentials, Auditory, Brain Stem/*physiology | 2 | 28.0 |
Kainic Acid/*pharmacology | 2 | 15.0 |
Neural Pathways/physiology | 2 | 6.0 |
Neurons/drug effects/physiology | 2 | 9.0 |
Ligation | 2 | 2.0 |
Laminin/metabolism | 7 | 6.0 |
Hyperlipoproteinemia/*drug therapy | 3 | 75.0 |
Lipoproteins, HDL/blood | 5 | 1.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Laminin/genetics | 2 | 11.0 |
Hyperlipoproteinemia/*blood | 6 | 24.0 |
Triglycerides/metabolism | 2 | 1.0 |
*Chromosome Deletion | 2 | 0.0 |
Electron Transport/*genetics | 2 | 33.0 |
Bleomycin/administration & dosage | 3 | 4.0 |
Doxorubicin/administration & dosage | 4 | 2.0 |
Mechlorethamine/administration & dosage | 2 | 25.0 |
Prednisone/administration & dosage | 2 | 2.0 |
Procarbazine/administration & dosage | 3 | 21.0 |
Remission Induction | 3 | 0.0 |
Vincristine/administration & dosage | 3 | 1.0 |
Neurilemmoma/*chemistry | 2 | 50.0 |
Fluorescence | 2 | 0.0 |
Glucosyltransferases/*metabolism | 2 | 33.0 |
*N-Acetylglucosaminyltransferases | 3 | 7.0 |
Peptide Mapping | 2 | 0.0 |
Procollagen/*genetics | 3 | 2.0 |
Lomustine/administration & dosage | 2 | 22.0 |
Fibroblasts/physiology | 2 | 1.0 |
Drug Evaluation | 5 | 2.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
DNA/genetics | 5 | 0.0 |
Arteries/*analysis/pathology | 2 | 100.0 |
Pepsin A | 5 | 35.0 |
Probability | 2 | 0.0 |
Blood Pressure | 3 | 0.0 |
*Cytochrome-c Oxidase Deficiency | 3 | 9.0 |
Basement Membrane/*analysis | 4 | 66.0 |
Japan | 3 | 0.0 |
Multicenter Studies | 2 | 1.0 |
Mycobacterium tuberculosis/*immunology | 2 | 3.0 |
Proline/metabolism | 2 | 3.0 |
Mitochondria/*enzymology/pathology | 2 | 100.0 |
Chromatography, Gel | 6 | 0.0 |
*Glottis | 2 | 50.0 |
NAD(P)H Dehydrogenase (Quinone) | 4 | 44.0 |
Liver/ultrastructure | 2 | 20.0 |
Propionates/*therapeutic use | 2 | 66.0 |
Extracellular Matrix/ultrastructure | 2 | 28.0 |
Risk | 4 | 0.0 |
Heparitin Sulfate/metabolism | 2 | 5.0 |
Carbon Radioisotopes/diagnostic use | 2 | 3.0 |
Peptides/analysis | 2 | 2.0 |
Amino Acids/analysis | 5 | 1.0 |
Paraffin Embedding | 2 | 0.0 |
Tissue Fixation | 2 | 2.0 |
Hypercholesterolemia, Familial/blood | 2 | 12.0 |
Hyperlipoproteinemia Type III/blood | 2 | 40.0 |
Hyperlipoproteinemia Type IV/blood | 2 | 20.0 |
Lipoproteins/*blood | 7 | 1.0 |
Fibrinolytic Agents/*pharmacology | 2 | 6.0 |
Platelet Adhesiveness/*drug effects | 2 | 6.0 |
Platelet Aggregation Inhibitors/*pharmacology | 2 | 3.0 |
Procollagen/classification/*genetics | 2 | 66.0 |
Erythrocytes/*enzymology | 3 | 0.0 |
Phosphoprotein Phosphatase/*blood | 2 | 66.0 |
Macaca fascicularis | 3 | 1.0 |
Macaca mulatta | 3 | 0.0 |
Blood Platelets/drug effects/*physiology | 2 | 4.0 |
Epoprostenol/*pharmacology | 2 | 20.0 |
Platelet Adhesiveness/drug effects | 2 | 4.0 |
Platelet Aggregation/drug effects | 5 | 2.0 |
Blood Platelets/drug effects/ultrastructure | 2 | 66.0 |
Platelet Aggregation | 2 | 1.0 |
Immunodiffusion | 3 | 1.0 |
Placenta/enzymology | 3 | 3.0 |
Electrophysiology | 2 | 0.0 |
HLA-D Antigens/*genetics | 2 | 1.0 |
Exertion | 3 | 4.0 |
Basement Membrane/analysis | 4 | 66.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Lipoproteins, LDL/metabolism | 2 | 0.0 |
Lipoproteins, VLDL/metabolism | 2 | 1.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Placenta/analysis | 2 | 9.0 |
Alcohol Drinking | 2 | 1.0 |
Obesity/complications | 2 | 4.0 |
Isoelectric Point | 2 | 1.0 |
Cholesterol/*blood | 3 | 1.0 |
Triglycerides/*blood | 5 | 1.0 |
Immunochemistry | 2 | 0.0 |
Basement Membrane/*immunology | 2 | 33.0 |
Cohort Studies | 2 | 0.0 |
Arteries/*metabolism/ultrastructure | 2 | 100.0 |
Collagen Type III/metabolism | 2 | 25.0 |
Collagen Type VI/metabolism | 2 | 50.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
Adenosine Diphosphate/pharmacology | 2 | 1.0 |
Diabetes Mellitus/physiopathology | 2 | 14.0 |
Electroretinography | 2 | 1.0 |
Lipoproteins, LDL/blood | 6 | 2.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Hyperlipoproteinemia/blood | 2 | 25.0 |
Lipoproteins, VLDL/blood | 5 | 2.0 |
Chemistry | 3 | 1.0 |
Peptide Fragments/*isolation & purification | 2 | 28.0 |
Muscles/ultrastructure | 2 | 40.0 |
Glycoproteins/*blood | 2 | 2.0 |
Body Weight | 3 | 0.0 |
Placenta/*analysis | 2 | 7.0 |
Placenta/immunology | 2 | 8.0 |
Living Donors | 2 | 4.0 |
Inclusion Bodies/ultrastructure | 2 | 8.0 |
Lipoproteins, VLDL/*analysis | 2 | 40.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Sheep | 2 | 0.0 |
Hemoglobins/analysis | 2 | 0.0 |
Viral Proteins/*analysis | 2 | 15.0 |
Hypercholesterolemia, Familial/blood/*drug therapy | 2 | 14.0 |
Hyperlipoproteinemia Type IV/blood/*drug therapy | 2 | 33.0 |
Nicotinic Acids/*therapeutic use | 2 | 40.0 |
Alkaline Phosphatase/blood | 2 | 1.0 |
Uric Acid/blood | 2 | 3.0 |
Hydroxyproline/metabolism | 2 | 22.0 |
Aspartate Aminotransferases/blood | 2 | 1.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Treatment Failure | 2 | 0.0 |
